Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

Abstract

Admission CRP predicts treatment non-response and time until next exacerbation. A very elevated admission CRP (>75mg/L) is highly specific for treatment non-response and might be used to target high-risk patients for future interventional studies aimed at improving exacerbation outcomes.